Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease

A method for differentiating stable chronic kidney disease (“CKD”) from progressive CKD in a subject diagnosed with CKD by:

• (a) determining the amount of Cystatin B polypeptides, clusterin polypeptides, or both, in a sample from the subject at a single time point,
• (b) comparing the amount of the Cystatin B polypeptides, clusterin polypeptides, or both in the sample to a control sample or control standard, wherein increased levels of Cystatin B polypeptides or clusterin polypeptides, or both in the sample as compared to the control sample or control standard is an indication of progressive CKD;
• and
• where the subject is indicated as having progressive CKD, further comprising administering one or more treatments to the subject comprising:
• surgery for obstructed ureters, obstructive nephroliths or uroliths, dietary management, administration of enteric phosphate binders, antiproteinurics, administration of antihypertensives, fluid therapy to correct dehydration, management of acidosis, administration of diuretics, dialysis, correction of electrolyte abnormalities, administration of antiemetics, administration of antacids, administration of recombinant erythropoietin, holistic treatment, or combinations thereof to the subject.